ID: ALA1922089

Max Phase: Preclinical

Molecular Formula: C20H12Cl4N2

Molecular Weight: 422.14

Molecule Type: Small molecule

Representations

Canonical SMILES:  Clc1ccc(Cn2c(-c3ccc(Cl)c(Cl)c3)nc3ccccc32)cc1Cl

Standard InChI:  InChI=1S/C20H12Cl4N2/c21-14-7-5-12(9-16(14)23)11-26-19-4-2-1-3-18(19)25-20(26)13-6-8-15(22)17(24)10-13/h1-10H,11H2

Standard InChI Key:  SXVQPGBAQBRVGX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 422.14

Molecular Weight (Monoisotopic): 419.9755

AlogP: 7.37

#Rotatable Bonds: 3

Polar Surface Area: 17.82

Molecular Species: NEUTRAL

HBA: 2

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 2

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 4.68

CX LogP: 7.65

CX LogD: 7.65

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.34

Np Likeness Score: -1.44

References

1. Bandyopadhyay P, Sathe M, Ponmariappan S, Sharma A, Sharma P, Srivastava AK, Kaushik MP..  (2011)  Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.,  21  (24): [PMID:22047695] [10.1016/j.bmcl.2011.10.034]

Source

Source(1):

• Scientific Literature